Status:
COMPLETED
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy
Lead Sponsor:
North Eastern German Society of Gynaecological Oncology
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
Determination of total survival under Topotecan Monotherapy, Topotecan + Etoposide and Topotecan + Gemcitabine in second-line therapy in patient with recurrent ovarian cancer.
Detailed Description
In Germany ovarian cancer belongs to the most frequently forms of cancer in the female population. The prognosis for women with a platin refractory ovarian cancer is very bad. The median survival time...
Eligibility Criteria
Inclusion
- Patient with recurrent ovarian cancer
- Second-line chemotherapy
- \> = 18 years of age
- ECOG \< = 2
Exclusion
- ECOG \> 2
- Patients with more than one chemotherapy in anamneses
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
End Date :
December 1 2009
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00312988
Start Date
January 1 2000
End Date
December 1 2009
Last Update
April 11 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Campus Virchow-Klinikum
Berlin, Germany, 13353